May 27, 2008 - BSD Medical Corp. said recently that several recent events have occurred in Europe that highlight the use of hyperthermia therapy in treating cancer.
Following the International Congress on Hyperthermic Oncology (ICHO) conducted last month in Munich, Germany, the joint annual meeting of the DEGRO Deutsche Gesellschaft fur Radio-Onkologie (German Society of Radiation Oncology) and OGRO Osterreichische Gesellschaft fur Radio-Onkologie (Austrian Society of Radiation Oncology) held in Vienna, Austria, also addressed hyperthermia therapy. In addition, there have been several new articles on hyperthermia therapy recently published.
“Hyperthermia as an Integral Component of Multimodality Therapy” was the theme of the Symposium on Hyperthermia Therapy at the joint annual meeting (DEGRO and OGRO) recently concluded in Vienna, Austria. The symposium was jointly chaired by Rolf Sauer, M.D., chairman of the Comprehensive Tumor Center of UMS Erlangen, and Frederik Wenz, M.D., chairman of Radiation-Oncology of the University Medical School at Mannheim-Heidelberg, Germany. Keynote speakers included prominent physicians and professors that routinely incorporate hyperthermia into their treatment of cancer, including Ellen Jones, M.D. (UMS Duke University, U.S.), Martine Franckena, M.D. (UMS Erasmus Rotterdam, Netherlands), Johanna Gellermann, M.D. (UMS Charite Berlin, Germany), Oliver Ott, M.D. and Udo Gaipl, Ph.D. (UMS Erlangen, Germany) and Frederik Wenz, M.D. (UMS Mannheim-Heidelberg, Germany). Dr. Gaipl strongly emphasized the potential of hyperthermia as the most potent radiation sensitizer available in cancer treatment.
In a recent publication of PHARMAZEUTISCHE ZEITUNG (PHARMACEUTICAL NEWS), Claudia Borchard Cloth described hyperthermia as “high tech warmth to fight against cancer.” She detailed how both deep and superficial hyperthermia effectively improves outcomes for conventional treatment methods like chemotherapy, radiation therapy and surgery. She explained that “tumor cells are particularly heat sensitive … temperatures over 40 degrees Celsius make them susceptible to attack from natural defense processes and radiation therapy.” She continues by stating “a number of new regional hyperthermia studies document survival data that is three times higher than standard therapy alone.”
In the “Technology and Medicine” section of the March issue of Hospital UMSCHAU, Claus Schwing addressed the benefits of hyperthermia therapy in an article titled “Hyperthermia – The Fourth Column of Cancer Treatment.” He quoted Dr. Ruediger Wessalowski from Dusseldorf as stating: “We are seeing amazing success with hyperthermia used in combination with other procedures.” He describes the alarming worldwide growth of cancer. In the past three years, the number of cancer patients in Europe increased from 2.9 million to 3.2 million. In 2009 Schwing estimates that 1.7 million Europeans will die of cancer.
For more information: www.BSDMedical.com